Clinicians Are Pushing for Smarter, Faster Depression Care
A new analysis published in Psychiatric Times is drawing attention to how NMDA receptor antagonists — the drug class that includes both IV ketamine and FDA-approved esketamine (Spravato) — are being used in treatment-resistant depression (TRD). The piece calls on prescribers to move faster and smarter: optimize dosing earlier, switch agents when one isn't working, and systematically track both symptom scores and adverse effects to help patients reach remission sooner rather than later.
The guidance comes at a pivotal moment. As ketamine and esketamine have become more accessible through telehealth platforms, questions around how well providers are monitoring side effects, measuring treatment response, and making data-informed adjustments have grown more urgent. This new clinical framing puts real pressure on providers — online and in-person alike — to raise the standard of care.
What the Research Actually Says About Side Effects and Stopping Treatment
NMDA receptor antagonists like ketamine and esketamine are among the most effective tools available for TRD, but they are not without tradeoffs. The Psychiatric Times analysis highlights that side effect profiles vary meaningfully across agents and delivery methods, and that discontinuation rates — patients stopping treatment before it has a chance to work — represent one of the biggest barriers to achieving remission.
Common side effects associated with ketamine-class treatments include dissociation, elevated blood pressure, nausea, dizziness, and sedation. For most patients, these effects are transient and manageable within a monitored clinical setting. But when providers fail to proactively screen for them, adjust dosing accordingly, or distinguish between tolerable side effects and warning signs, patients are more likely to discontinue prematurely — leaving their depression undertreated.
The analysis emphasizes that standardized tools like the PHQ-9 (a validated depression symptom scale) should be used consistently throughout treatment to objectively measure progress. This kind of structured tracking, the authors argue, should drive clinical decisions — including when to escalate a dose, when to hold, and when to pivot to a different approach entirely.
Why This Matters for Online Ketamine Treatment
For patients exploring telehealth ketamine options in 2026, this analysis is a useful lens for evaluating providers. The clinical bar being described — routine PHQ-9 tracking, proactive side effect monitoring, willingness to adjust doses rather than keep patients on a fixed protocol indefinitely — is exactly what distinguishes high-quality online ketamine programs from lower-touch services that simply ship medication and check in monthly.
Online ketamine treatment has expanded access dramatically, particularly for patients in areas without local infusion clinics or psychiatrists experienced with TRD. That access is genuinely valuable. But the tradeoff of convenience cannot come at the cost of clinical rigor. The research being discussed in Psychiatric Times reflects a growing consensus in psychiatry: passive treatment management leads to higher discontinuation, slower remission, and worse long-term outcomes.
Specifically, patients considering online ketamine should look for providers who use standardized screening tools before and throughout treatment, ask about your complete medication history and past treatment trials, explain how they will monitor and respond to side effects, have a clear protocol for dose adjustments based on your response, and offer access to a clinician — not just a care coordinator — when questions arise between sessions.
Providers who treat ketamine as a one-size-fits-all protocol rather than an individually titrated intervention are more likely to produce the discontinuation rates this research flags as problematic.
Key Takeaway for Patients
Not all online ketamine programs track your progress the same way. Before starting treatment, ask your provider how they measure symptom improvement (PHQ-9 or similar), how they handle side effects, and under what conditions they would adjust your dose or recommend a different approach. A provider who can answer these questions clearly is one operating at the standard this new clinical guidance recommends.
The Bigger Picture: Toward Remission, Not Just Relief
One of the most important framings in the Psychiatric Times piece is the distinction between symptom response and full remission. A patient who feels somewhat better after initial ketamine sessions has responded — but response is not the goal. Remission, defined as a sustained return to baseline functioning with minimal depressive symptoms, is. Getting there requires ongoing clinical attention, not just an initial prescription.
For patients with treatment-resistant depression who have tried multiple antidepressants without adequate relief, ketamine represents a legitimate and evidence-backed option. But the data now available on NMDA receptor antagonists makes clear that how a provider manages the treatment — the monitoring, the titration, the willingness to adapt — matters as much as the medication itself.
As online ketamine access continues to grow, the quality gap between providers will increasingly define patient outcomes. This latest clinical analysis is a reminder that good ketamine care is active, not passive. The best providers in the telehealth space already operate this way. This research gives patients the language to ask for it — and reason to expect it as a baseline.
Read the original analysis at Psychiatric Times.
Share